JP2019055934A - Cholesterol reducing agents and methods of manufacturing the same - Google Patents
Cholesterol reducing agents and methods of manufacturing the same Download PDFInfo
- Publication number
- JP2019055934A JP2019055934A JP2017247605A JP2017247605A JP2019055934A JP 2019055934 A JP2019055934 A JP 2019055934A JP 2017247605 A JP2017247605 A JP 2017247605A JP 2017247605 A JP2017247605 A JP 2017247605A JP 2019055934 A JP2019055934 A JP 2019055934A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- intake
- molecular weight
- weeks
- protease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 61
- 235000012000 cholesterol Nutrition 0.000 title claims abstract description 25
- 239000003638 chemical reducing agent Substances 0.000 title claims description 21
- 238000004519 manufacturing process Methods 0.000 title claims description 18
- 238000000034 method Methods 0.000 title description 26
- 239000000203 mixture Substances 0.000 claims abstract description 156
- 108091005804 Peptidases Proteins 0.000 claims abstract description 68
- 239000004365 Protease Substances 0.000 claims abstract description 68
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 66
- 238000000354 decomposition reaction Methods 0.000 claims abstract description 39
- 210000004369 blood Anatomy 0.000 claims abstract description 37
- 239000008280 blood Substances 0.000 claims abstract description 37
- 230000035487 diastolic blood pressure Effects 0.000 claims abstract description 31
- 230000008407 joint function Effects 0.000 claims abstract description 25
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 78
- 229920002674 hyaluronan Polymers 0.000 claims description 77
- 229960003160 hyaluronic acid Drugs 0.000 claims description 77
- 239000007857 degradation product Substances 0.000 claims description 46
- 239000000047 product Substances 0.000 claims description 43
- 241000287828 Gallus gallus Species 0.000 claims description 38
- 235000018102 proteins Nutrition 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 235000001014 amino acid Nutrition 0.000 claims description 26
- 229940024606 amino acid Drugs 0.000 claims description 26
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 102000004190 Enzymes Human genes 0.000 claims description 22
- 108090000790 Enzymes Proteins 0.000 claims description 22
- 210000000629 knee joint Anatomy 0.000 claims description 17
- 230000000593 degrading effect Effects 0.000 claims description 12
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 9
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 9
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 9
- QCHPKSFMDHPSNR-UHFFFAOYSA-N 3-aminoisobutyric acid Chemical compound NCC(C)C(O)=O QCHPKSFMDHPSNR-UHFFFAOYSA-N 0.000 claims description 8
- 235000013361 beverage Nutrition 0.000 claims description 7
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- 235000003704 aspartic acid Nutrition 0.000 claims description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 5
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 229960003067 cystine Drugs 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 235000008729 phenylalanine Nutrition 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims 1
- 230000009471 action Effects 0.000 abstract description 51
- 230000001603 reducing effect Effects 0.000 abstract description 32
- 208000002193 Pain Diseases 0.000 description 38
- 239000002775 capsule Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 229940088598 enzyme Drugs 0.000 description 18
- 238000011156 evaluation Methods 0.000 description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 17
- 239000008103 glucose Substances 0.000 description 17
- 230000008859 change Effects 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 13
- 208000006820 Arthralgia Diseases 0.000 description 12
- 239000000843 powder Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 208000008035 Back Pain Diseases 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000032683 aging Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000033001 locomotion Effects 0.000 description 8
- 210000003127 knee Anatomy 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 208000008930 Low Back Pain Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000004375 Dextrin Substances 0.000 description 5
- 229920001353 Dextrin Polymers 0.000 description 5
- 235000019425 dextrin Nutrition 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000006866 deterioration Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 208000024765 knee pain Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003349 osteoarthritic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- FRBUNLLUASHNDJ-UHFFFAOYSA-N (2-nitrophenyl)hydrazine Chemical compound NNC1=CC=CC=C1[N+]([O-])=O FRBUNLLUASHNDJ-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Abstract
Description
本発明は、組成物およびその組成物を製造する方法に関する。 The present invention relates to compositions and methods of making the compositions.
ヒアルロン酸は、保湿効果や保水効果を高める働きがあることが知られており、従来からさまざまな化粧品や医薬品に配合されている。例えば、乾燥肌や荒れ肌に直接適用することにより保湿性を高めて肌のコンディションを調えたり、乾燥期に皮膚表面から水分が失われたりすることを防ぐために予防的に皮膚表面に適用することが通常行われている。また、ヒアルロン酸は、保湿効果から派生する機能や保湿効果以外の有用な特性の発現も期待され、その新たな利用法に関する研究も幾つか見受けられる。 Hyaluronic acid is known to have a function of enhancing the moisturizing effect and the water retaining effect, and has been conventionally blended in various cosmetics and medicines. For example, it may be applied preventively to the skin surface to improve moisturizing and conditioning the skin by applying it directly to dry skin or rough skin, or to prevent loss of water from the skin surface during the dry season. It is usually done. Hyaluronic acid is also expected to exhibit functional properties derived from the moisturizing effect and useful properties other than the moisturizing effect, and there are also some studies on its new usage.
例えば、特許文献１には、ヒアルロン酸と蛋白質とを含有する組成物をプロテアーゼで分解した分解生成物を創傷治療剤に用いることが提案されている。この創傷治療剤は、生体成分であるヒアルロン酸や蛋白質、反応が緩和な酵素を用いているために安全性が高く、例えば経口投与や創傷部位への直接投与により創傷を迅速に治療することができる。 For example, Patent Document 1 proposes that a decomposition product obtained by degrading a composition containing hyaluronic acid and a protein with a protease is used as a wound healing agent. The agent for treating wounds is highly safe because it uses hyaluronic acid or protein which is a biological component, and an enzyme with a mild reaction, for example, it can rapidly treat wounds by oral administration or direct administration to the wound site. it can.
上記のように、ヒアルロン酸と蛋白質とを含有する組成物をプロテアーゼで分解した分解生成物は、創傷治療剤として高い有用性を有する。しかし、この分解生成物は、創傷治療効果等が確認されているだけで他の作用効果は殆ど知られておらず、応用範囲が限られていた。 As described above, the decomposition product of the composition containing hyaluronic acid and protein and degraded by protease has high utility as a wound treatment agent. However, this decomposition product has only been confirmed for its wound healing effect and the like, and its other effects are hardly known, and its application range is limited.
一方、近年、「アンチエイジング」に大きな関心が寄せられている。「アンチエイジング」とは、加齢に伴う老化の原因を抑制することによって、身体の機能的な衰え（老化）を予防したり改善したりすることである。加齢による身体機能の衰えには、腰や膝などの関節痛、関節可動域の減少、高血圧症、代謝変調による高コレステロール血症や高血糖症等が挙げられ、いずれも進行すれば生活の質が損なわれ、日常生活に様々な支障をきたすことになる。
そのため、そうした加齢による身体機能の衰えを予防、改善することを目的とした医薬、サプリメント、飲料として様々なものが開発され、日常的に使用されている。しかし、それらの効果には個人差があり、既存の製品では十分な効果が得られない場合もある。このような状況から、上記のような加齢に伴う身体機能の衰えを改善しうる新たな組成物の開発が切望まれている。
On the other hand, in recent years, there has been great interest in "anti-aging". "Anti-aging" is to prevent or improve functional deterioration of the body (aging) by suppressing the causes of aging associated with aging. Deterioration of physical function due to aging includes joint pain such as hips and knees, decrease in range of motion, hypertension, hypercholesterolemia and hyperglycemia due to metabolic modulation, etc. The quality is lost and it causes various problems in daily life.
Therefore, various medicines, supplements and beverages for the purpose of preventing and improving the deterioration of the physical function due to such aging are developed and used daily. However, there are individual differences in their effects, and existing products may not provide sufficient effects. From such a situation, development of a new composition which can improve the decline in physical function accompanying aging as described above is desired.
そこで本発明者らは、このような従来技術の課題を解決するために、関節痛や関節機能の衰え、代謝機能の変調、高血圧症を改善しうる新たな組成物を提供することを課題として検討を進めた。また、そのような組成物を安価に製造することができる製造方法を提供することを課題として検討を進めた。 Therefore, in order to solve such problems of the prior art, the present inventors set as a problem to provide a new composition capable of improving joint pain, deterioration of joint function, modulation of metabolic function and hypertension. We proceeded with the examination. In addition, the present inventors have made investigations with an object of providing a manufacturing method that can manufacture such a composition inexpensively.
上記の課題を解決するために鋭意検討を行った結果、本発明者らは、上記の創傷治療作用があることが知られている組成物、すなわちヒアルロン酸と蛋白質とを含有する組成物をプロテアーゼで分解した分解生成物に疼痛緩和作用、関節機能改善作用、コレステロール低減作用、血糖低減作用および拡張期血圧低下作用があることを初めて見出した。そして、この分解生成物のこれらの作用を利用することにより、安全性の高い疼痛緩和剤、関節機能改善剤、コレステロール低減剤、血糖低減剤または拡張期血圧低下剤を安価で提供できることを見出すに至った。本発明は、これらの知見に基づいて提案されたものであり、具体的に以下の構成を有する。 As a result of intensive studies to solve the above problems, the present inventors have been able to use the above composition known to have a wound healing effect, ie, a composition containing hyaluronic acid and a protein as a protease. It has been found for the first time that there are pain-relieving actions, joint function improving actions, cholesterol reducing actions, blood sugar reducing actions and diastolic blood pressure lowering actions in decomposition products decomposed by Then, it is found that by utilizing these actions of this degradation product, it is possible to provide a highly safe pain relieving agent, joint function improving agent, cholesterol reducing agent, blood sugar reducing agent or diastolic blood pressure reducing agent at low cost. It reached. The present invention has been proposed based on these findings, and specifically has the following configuration.
［１］ ヒアルロン酸と蛋白質とを含有する組成物をプロテアーゼで分解した分解生成物を含有する組成物であって、
疼痛緩和剤、関節機能改善剤、コレステロール低減剤、血糖低減剤または拡張期血圧低下剤のいずれかである組成物。
［２］ 疼痛緩和剤である、［１］に記載の組成物。
［３］ 膝関節痛緩和剤である、［２］に記載の組成物。
［４］ 腰痛緩和剤である、［２］に記載の組成物。
［５］ 関節機能改善剤である、［１］に記載の組成物。
［６］ 膝関節可動域開大剤である、［５］に記載の組成物。
［７］ コレステロール低減剤である、［１］に記載の組成物。
［８］ 血糖低減剤である、［１］に記載の組成物。
［９］ 拡張期血圧低下剤である、［１］に記載の組成物。
［１０］ 前記ヒアルロン酸と蛋白質とを含有する組成物が鶏冠であることを特徴とする［１］〜［９］のいずれか１項に記載の組成物。
［１１］ 前記分解生成物が、分子量が３８０〜５０００の低分子ヒアルロン酸を含有することを特徴とする［１］〜［１０］のいずれか１項に記載の組成物。
［１２］ 前記分子量が３８０〜５０００の低分子ヒアルロン酸の含有量が、組成物の全量に対して１０質量％以上であることを特徴とする［１１］に記載の組成物。
［１３］ 分子量が１５２０〜５０００の低分子ヒアルロン酸の割合が、分子量が３８０〜５０００の低分子ヒアルロン酸全量の６０質量％以上であることを特徴とする［１１］または［１２］に記載の組成物。
［１４］ Ｎ−アセチルグルコサミンの含有量が、組成物の全量に対して０．０１質量％以下であることを特徴とする［１］〜［１３］のいずれか１項に記載の組成物。
［１５］ 総遊離アミノ酸量が組成物の全量に対する質量比で２質量％以上であり、且つ、総蛋白質量が組成物の全量に対する質量比で２質量％以上であることを特徴とする［１］〜［１４］のいずれか１項に記載の組成物。
［１６］ 前記遊離アミノ酸が、イソロイシン、β−アミノイソ酪酸、アラニン、フェニルアラニン、アスパラギン酸、シスチンおよびチロシンから選択される少なくとも１種を含有することを特徴とする［１５］に記載の組成物。
［１７］ 前記分解生成物の凍結乾燥物を粉砕して得た粉砕物を含むことを特徴とする［１］〜［１６］のいずれか１項に記載の組成物。
[1] A composition comprising a decomposition product obtained by degrading a composition containing hyaluronic acid and a protein with a protease,
A composition which is either a pain relieving agent, a joint function improving agent, a cholesterol reducing agent, a blood glucose reducing agent or a diastolic blood pressure reducing agent.
[2] The composition according to [1], which is a pain relieving agent.
[3] The composition according to [2], which is a knee joint pain reliever.
[4] The composition according to [2], which is a low back pain relieving agent.
[5] The composition according to [1], which is a joint function improving agent.
[6] The composition according to [5], which is a knee joint movable area widening agent.
[7] The composition according to [1], which is a cholesterol reducing agent.
[8] The composition according to [1], which is a blood sugar reducing agent.
[9] The composition according to [1], which is a diastolic blood pressure reducing agent.
[10] The composition according to any one of [1] to [9], wherein the composition containing hyaluronic acid and protein is a chicken crown.
[11] The composition according to any one of [1] to [10], wherein the decomposition product contains low molecular weight hyaluronic acid having a molecular weight of 380 to 5,000.
[12] The composition according to [11], wherein the content of the low molecular weight hyaluronic acid having a molecular weight of 380 to 5,000 is 10% by mass or more with respect to the total amount of the composition.
[13] The proportion of low molecular weight hyaluronic acid having a molecular weight of 1520 to 5000 is 60% by mass or more of the total amount of low molecular weight hyaluronic acid having a molecular weight of 380 to 5000, according to [11] or [12] Composition.
[14] The composition according to any one of [1] to [13], wherein the content of N-acetylglucosamine is 0.01% by mass or less based on the total amount of the composition.
[15] It is characterized in that the total free amino acid amount is 2% by mass or more in mass ratio to the total amount of the composition, and the total protein mass is 2% by mass or more in mass ratio to the total amount of the composition [1 ] The composition as described in any one of-[14].
[16] The composition according to [15], wherein the free amino acid contains at least one selected from isoleucine, β-aminoisobutyric acid, alanine, phenylalanine, aspartic acid, cystine and tyrosine.
[17] The composition according to any one of [1] to [16], which comprises a pulverized product obtained by pulverizing a lyophilizate of the decomposition product.
［１８］ 医薬組成物である、［１］〜［１７］のいずれか１項に記載の組成物。
［１９］ 食品である、［１］〜［１７］のいずれか１項に記載の組成物。
［２０］ 飲料である、［１］〜［１７］のいずれか１項に記載の組成物。
［２１］ 化粧品である、［１］〜［１７］のいずれか１項に記載の組成物。
[18] The composition according to any one of [1] to [17], which is a pharmaceutical composition.
[19] The composition according to any one of [1] to [17], which is a food.
[20] The composition according to any one of [1] to [17], which is a beverage.
[21] The composition according to any one of [1] to [17], which is a cosmetic.
［２２］ ヒアルロン酸と蛋白質とを含有する組成物をプロテアーゼで分解する酵素処理工程を含むことを特徴とする、疼痛緩和剤、関節機能改善剤、コレステロール低減剤、血糖低減剤または拡張期血圧低下剤の製造方法。
［２３］ 前記ヒアルロン酸と蛋白質とを含有する組成物が鶏冠であり、前記酵素処理工程の前に、前記鶏冠を１辺０．５ｃｍ角以上に小片化する工程を有することを特徴とする［２２］に記載の製造方法。
［２４］ 前記酵素処理工程の後に、前記酵素処理工程で得た分解生成物を、凍結乾燥した後、粉砕して粉砕物を得る工程を有することを特徴とする［２２］または［２３］に記載の製造方法。
［２５］ 前記酵素処理工程の後に、前記酵素処理工程で得た分解生成物を精製する精製工程を有することを特徴とする［２２］〜［２４］のいずれか１項に記載の製造方法。
[22] A pain relieving agent, a joint function improving agent, a cholesterol reducing agent, a blood glucose reducing agent or diastolic blood pressure lowering characterized by comprising an enzyme treatment step of degrading a composition containing hyaluronic acid and protein with a protease Method of preparation of
[23] The composition containing the hyaluronic acid and the protein is a chicken crown, and the method comprises cutting the chicken crown into 0.5 cm square or more per side prior to the enzyme treatment step. 22].
[24] After the enzyme treatment step, the degradation product obtained in the enzyme treatment step is freeze-dried and then crushed to obtain a ground product [22] or [23] Manufacturing method described.
[25] The method according to any one of [22] to [24], further comprising a purification step of purifying the decomposition product obtained in the enzyme treatment step after the enzyme treatment step.
本発明の組成物は、疼痛緩和作用、関節機能改善作用、コレステロール低減作用、血糖低減作用および拡張期血圧低下作用を有し、これらの作用を薬効とする医薬品に効果的に用いることができる。また、本発明の組成物の製造方法によれば、上記の有用な作用効果を奏する組成物を低コストで製造することができる。 The composition of the present invention has pain relieving action, joint function improving action, cholesterol reducing action, blood glucose reducing action and diastolic blood pressure reducing action, and can be effectively used for medicines which make these effects effective. Moreover, according to the method for producing a composition of the present invention, a composition having the above-mentioned useful effects can be produced at low cost.
以下において、本発明について詳細に説明する。以下に記載する構成要件の説明は、代表的な実施形態や具体例に基づいてなされることがあるが、本発明はそのような実施形態に限定されるものではない。なお、本明細書において「〜」を用いて表される数値範囲は「〜」前後に記載される数値を下限値及び上限値として含む範囲を意味する。 Hereinafter, the present invention will be described in detail. The description of the configuration requirements described below may be made based on typical embodiments and specific examples, but the present invention is not limited to such embodiments. In addition, the numerical range represented using "-" in this specification means the range which includes the numerical value described before and after "-" as a lower limit and an upper limit.
［組成物］
本発明の組成物は、ヒアルロン酸と蛋白質とを含有する組成物をプロテアーゼで分解した分解生成物を含有する点に特徴がある。
[Composition]
The composition of the present invention is characterized in that it contains a decomposition product obtained by protease decomposition of a composition containing hyaluronic acid and a protein.
上記組成物に含まれるヒアルロン酸は、化粧品や医薬品の成分として通常用いられているヒアルロン酸であれば特に制限なく使用することができる。ヒアルロン酸は、元来ウシの眼の硝子体から単離されたものであるが、これに限らず、動物の関節液やニワトリの鶏冠などから単離されたものであっても使用することができる。また、自然界から単離されたものでなく、合成や微生物発酵法により得られたものでもよい。 The hyaluronic acid contained in the above-mentioned composition can be used without particular limitation as long as it is a hyaluronic acid generally used as a component of cosmetics and pharmaceuticals. Hyaluronic acid is originally isolated from the vitreous body of bovine eyes, but it is not limited thereto, and it may be used even if it is isolated from animal synovial fluid or chicken crown it can. Moreover, it may not be isolated from nature but may be obtained by synthesis or microbial fermentation.
ヒアルロン酸は、アミノ酸とウロン酸からなる複雑な多糖類であるが、その構造の詳細は特に限定されない。例えば、Ｄ−グルクロン酸とＮ−アセチル−Ｄ−グルコサミンからなるニ糖を繰り返し単位とする多糖を挙げることができる。組成物に含まれるヒアルロン酸の分子量は特に限定されないが、例えば鶏冠に含まれるヒアルロン酸は、分子量が６００万〜１０００万であり、鶏冠から抽出したヒアルロン酸は、抽出過程で分解されるため、平均分子量が数十万〜数百万である。本発明で使用するヒアルロン酸は、本発明の組成物としたときに、疼痛緩和作用、関節機能改善作用、コレステロール低減作用、血糖低減作用および拡張期血圧低下作用のうちの少なくとも１つの作用を過度に失わないものである限り、誘導化や熱変性を受けたものであっても構わない。いわゆるヒアルロン酸誘導体として知られている化合物は、本発明で有効に使用することができる。 Hyaluronic acid is a complex polysaccharide consisting of amino acid and uronic acid, but the details of its structure are not particularly limited. For example, polysaccharides having a disaccharide consisting of D-glucuronic acid and N-acetyl-D-glucosamine as a repeating unit can be mentioned. The molecular weight of hyaluronic acid contained in the composition is not particularly limited. For example, hyaluronic acid contained in the chicken crown has a molecular weight of 6 to 10,000,000 and hyaluronic acid extracted from the chicken crown is degraded in the extraction process, The average molecular weight is hundreds of thousands to millions. The hyaluronic acid used in the present invention, when formulated into the composition of the present invention, has an excessive effect on at least one of pain relieving action, joint function improving action, cholesterol reducing action, blood glucose reducing action and diastolic blood pressure reducing action. It may be derivatized or thermally denatured as long as it does not lose its strength. Compounds known as so-called hyaluronic acid derivatives can be used effectively in the present invention.
上記組成物に含まれる蛋白質はその種類を問わないが、鶏冠に含まれる蛋白質が極めて好ましい。鶏冠の種類は特に制限されないが、ニワトリの鶏冠を用いるのが好ましい。ニワトリの鶏冠はヒアルロン酸を含有するため、本発明の組成物の製造に用いる組成物（ヒアルロン酸と蛋白質とを含有する組成物）を提供するに際して、鶏冠にヒアルロン酸を別途添加しなくてもよいというメリットがある。このため、鶏冠を用いれば本発明の組成物の製造工程が簡略化でき、製造コストも下げることができる。 Although the protein contained in the said composition does not matter in the kind, the protein contained in a chicken crown is very preferable. Although the type of chicken crown is not particularly limited, it is preferable to use a chicken crown. Since the chicken crown of a chicken contains hyaluronic acid, when providing the composition (composition containing hyaluronic acid and a protein) used for producing the composition of the present invention, even without separately adding hyaluronic acid to the chicken crown, It has the merit of being good. For this reason, if a chicken crown is used, the manufacturing process of the composition of the present invention can be simplified, and the manufacturing cost can also be reduced.
本発明で用いる組成物は、蛋白質とヒアルロン酸のみを含んでいてもよいし、その他の成分や溶媒、分散媒を含んでいてもよい。溶媒および分散媒としては、蛋白質やヒアルロン酸を溶解できるものであればよく、水や水性緩衝液を好適に用いることができる。また、組成物は、蛋白質とヒアルロン酸を含む天然物そのものであってもよい。組成物となる天然物としては、動物の関節液や鶏冠を挙げることができ、ヒアルロン酸を豊富に含むことからニワトリの鶏冠であることが好ましい。 The composition used in the present invention may contain only protein and hyaluronic acid, and may contain other components, a solvent, and a dispersion medium. As the solvent and the dispersion medium, any one capable of dissolving protein and hyaluronic acid may be used, and water and an aqueous buffer can be suitably used. The composition may also be a natural product itself comprising protein and hyaluronic acid. Examples of natural products to be used as the composition include joint fluid and chicken crown of animals, and it is preferably chicken crown because it is rich in hyaluronic acid.
本発明で用いる分解生成物は、上記の組成物をプロテアーゼで分解したものである。プロテアーゼの種類は特に制限されない。通常の蛋白質分解に用いられるプロテアーゼであればいずれも使用することができる。すなわち、エンドペプチダーゼであっても、エキソぺプチダーゼであっても使用することが可能であり、また活性部位はセリン、システイン、金属、アスパラギン酸等のいずれであってもよい。また、複数のプロテアーゼを混合して使用してもよい。好ましいプロテアーゼとして、例えばプロナーゼを使用することができる。 The degradation products used in the present invention are those obtained by degrading the above composition with a protease. The type of protease is not particularly limited. Any protease that is used for normal proteolysis can be used. That is, it is possible to use either endopeptidase or exopeptidase, and the active site may be any of serine, cysteine, metal, aspartic acid and the like. Also, a plurality of proteases may be mixed and used. As a preferred protease, for example, pronase can be used.
また、本発明で用いる分解生成物は、上記の組成物をプロテアーゼで分解したものであるため、少なくとも、プロテアーゼにより分解された蛋白質の分解物と、ヒアルロン酸を含有し、未分解の蛋白質（プロテアーゼ添加前の組成物に元々含まれていた蛋白質）や組成物由来の他の成分を含有していてもよい。
分解生成物に含まれる蛋白質の分解物としては、未分解の蛋白質よりも低分子量の蛋白質、ペプチド、遊離アミノ酸を挙げることができ、これらが混在していてもよい。
また、分解生成物は、遊離アミノ酸を含有することが好ましい。分解生成物が含有する遊離アミノ酸は、蛋白質の分解物としての遊離アミノ酸であってもよいし、プロテアーゼ添加前の組成物に遊離アミノ酸として元々含まれていたものであってもよい。遊離アミノ酸の種類は、組成物の成分によっても異なるが、例えば組成物が鶏冠である分解生成物では、比較的含有率が多いアミノ酸としてイソロイシン、β−アミノイソ酪酸、アラニン、フェニルアラニン、アスパラギン酸、シスチン、チロシン等を挙げることができ、この他にも、多種類のアミノ酸を含む。
In addition, since the degradation product used in the present invention is obtained by degrading the above composition with a protease, it contains at least a degradation product of a protein degraded by the protease and hyaluronic acid and is a non-degraded protein (protease It may contain other components derived from the composition) and proteins originally contained in the composition before addition.
Examples of protein degradation products contained in the degradation products include proteins, peptides and free amino acids of lower molecular weight than undegraded proteins, and these may be mixed.
Moreover, it is preferable that the decomposition product contains a free amino acid. The free amino acid contained in the degradation product may be a free amino acid as a protein degradation product, or may be originally contained as a free amino acid in the composition before addition of the protease. Although the type of free amino acid varies depending on the components of the composition, for example, in the degradation product whose composition is a chicken crown, isoleucine, β-aminoisobutyric acid, alanine, phenylalanine, aspartic acid, cystine as a relatively high content amino acid And tyrosine etc., and in addition to this, it contains many kinds of amino acids.
本発明の組成物における総蛋白質量は、組成物の全量に対する質量比で０．５〜１０質量％であることが好ましく、１〜７質量％であることがより好ましく、２〜５質量％であることがさらに好ましい。また、本発明の組成物における総遊離アミノ酸量は、組成物の全量に対する質量比で０．５〜１２質量％であることが好ましく、１〜８質量％であることがより好ましく、２〜６質量％であることがさらに好ましい。本発明の組成物における総蛋白質量および遊離アミノ酸量が上記の範囲であることにより、組成物が効果的に作用すると考えられ、疼痛緩和作用、関節機能改善作用、コレステロール低減作用、血糖低減作用および拡張期血圧低下作用を顕著に得ることができる。
本明細書中において「総蛋白質量」とは、Lowry法により求めた総蛋白質含量のことをいい、「総遊離アミノ酸量」とは、Ninhydrin法により求めた遊離アミノ酸の総量のことをいう。
The total protein mass in the composition of the present invention is preferably 0.5 to 10 mass%, more preferably 1 to 7 mass%, and 2 to 5 mass% in mass ratio to the total mass of the composition. It is further preferred that The total free amino acid content in the composition of the present invention is preferably 0.5 to 12% by mass, more preferably 1 to 8% by mass, in terms of mass ratio to the total amount of the composition, and 2 to 6 More preferably, it is mass%. When the total protein mass and free amino acid content in the composition of the present invention are in the above range, the composition is considered to act effectively, and the pain relieving action, joint function improving action, cholesterol reducing action, blood glucose reducing action and The diastolic blood pressure lowering action can be significantly obtained.
In the present specification, “total protein mass” refers to the total protein content determined by the Lowry method, and “total free amino acid amount” refers to the total amount of free amino acids determined by the Ninhydrin method.
上記の分解生成物に含まれるヒアルロン酸は、プロテアーゼ添加前の組成物に元々含まれていたヒアルロン酸がそのまま残存したもの（以下、「未分解のヒアルロン酸」という）であってもよいし、ヒアルロン酸の分解物（以下、「低分子ヒアルロン酸」という）であってもよいし、未分解のヒアルロン酸と低分子ヒアルロン酸とが混在したものであってもよいが、低分子ヒアルロン酸を含有することが好ましい。低分子ヒアルロン酸は生命体の深部に浸透し易く、生命体に対する作用を効果的に得ることができる。分解生成物が含有する低分子ヒアルロン酸は、組成物中でヒアルロン酸を加水分解させて得た低分子ヒアルロン酸であってもよいし、上記の組成物とは別の系でヒアルロン酸を加水分解し、得られた低分子ヒアルロン酸を分解生成物に添加したものであってもよいが、組成物中でヒアルロン酸を加水分解させて得た低分子ヒアルロン酸であることが好ましい。組成物中での低分子ヒアルロン酸の生成は、塩酸やヒアルロニダーゼ等の、ヒアルロン酸を加水分解する物質を組成物に添加することにより行うことができる。また、組成物が天然物である場合には、天然物に元々含まれる物質による自己消化を利用して低分子ヒアルロン酸を生成してもよい。ただし、ヒアルロン酸の生体に対する作用を有効に得る点から、ヒアルロン酸は構成単位を保持していること、すなわち、グルクロン酸とＮ−アセチルグルコサミンまで分解が進行していないことが好ましい。具体的には、本発明の組成物におけるＮ−アセチルグルコサミンの含有量は、組成物の全量に対して０．０１質量％以下であることが好ましく、０質量％であることが最も好ましい。
本明細書中において「Ｎ−アセチルグルコサミン量」とはMorgan-Elson法により求めたＮ−アセチルグルコサミン含量のことをいう。
The hyaluronic acid contained in the above-mentioned degradation product may be one in which the hyaluronic acid originally contained in the composition before the addition of the protease remains as it is (hereinafter referred to as "non-degraded hyaluronic acid"), It may be a decomposition product of hyaluronic acid (hereinafter referred to as “low molecular weight hyaluronic acid”), or it may be a mixture of undegraded hyaluronic acid and low molecular weight hyaluronic acid. It is preferable to contain. Low molecular weight hyaluronic acid can easily penetrate deep into the living body, and can effectively obtain an action on the living body. The low molecular weight hyaluronic acid contained in the degradation product may be a low molecular weight hyaluronic acid obtained by hydrolyzing hyaluronic acid in the composition, or the hyaluronic acid may be hydrolyzed in a system different from the above composition. Although the low molecular weight hyaluronic acid obtained by being decomposed may be added to the decomposition product, the low molecular weight hyaluronic acid obtained by hydrolyzing the hyaluronic acid in the composition is preferable. The production of low molecular weight hyaluronic acid in the composition can be carried out by adding a substance that hydrolyzes hyaluronic acid, such as hydrochloric acid or hyaluronidase, to the composition. In addition, when the composition is a natural product, low-molecular-weight hyaluronic acid may be produced using autolysis by a substance originally contained in the natural product. However, from the viewpoint of effectively obtaining the action of hyaluronic acid on a living body, it is preferable that hyaluronic acid holds a structural unit, that is, degradation to glucuronic acid and N-acetylglucosamine has not progressed. Specifically, the content of N-acetylglucosamine in the composition of the present invention is preferably 0.01% by mass or less with respect to the total amount of the composition, and most preferably 0% by mass.
In the present specification, the "N-acetylglucosamine amount" refers to the N-acetylglucosamine content determined by the Morgan-Elson method.
分解生成物が含有する低分子ヒアルロン酸は、分子量が３８０〜５０００であることが好ましい。分子量３８０〜５０００は、ヒアルロン酸の繰り返し単位数で約１〜１４に相当する。本発明の組成物における、分子量３８０〜５０００の低分子ヒアルロン酸の含有量は、組成物の全量に対して５質量％以上であることが好ましく、７質量％以上であることがより好ましく、１０質量％以上であることがさらに好ましい。また、低分子ヒアルロン酸のうちでは、分子量１５２０〜５０００の低分子ヒアルロン酸が主成分であることが好ましく、分子量１５２０〜５０００の低分子ヒアルロン酸の割合が分子量３８０〜５０００の低分子ヒアルロン酸全量の６０質量％以上であることが好ましく、７０質量％以上であることがより好ましく、７５質量％以上であることがさらに好ましい。これにより、本発明の組成物が効果的に作用すると考えられ、疼痛緩和作用、関節機能改善作用、コレステロール低減作用、血糖低減作用および拡張期血圧低下作用を顕著に発揮することができる。
低分子ヒアルロン酸の分子量と質量比率は、ポリエチレングリコールを分子量マーカーに用いる高速液体クロマトグラフィにより分析することができる。
The low molecular weight hyaluronic acid contained in the degradation product preferably has a molecular weight of 380 to 5,000. The molecular weight of 380 to 5000 corresponds to about 1 to 14 in the number of repeating units of hyaluronic acid. The content of the low molecular weight hyaluronic acid having a molecular weight of 380 to 5,000 in the composition of the present invention is preferably 5% by mass or more, more preferably 7% by mass or more, based on the total amount of the composition. It is further preferable that the content is at least% by mass. Among low molecular weight hyaluronic acid, low molecular weight hyaluronic acid having a molecular weight of 1520 to 5000 is preferably the main component, and the proportion of low molecular weight hyaluronic acid having a molecular weight of 1520 to 5000 is the total amount of low molecular weight hyaluronic acid having a molecular weight of 380 to 5000 The content is preferably 60% by mass or more, more preferably 70% by mass or more, and still more preferably 75% by mass or more. Thereby, it is considered that the composition of the present invention works effectively, and the pain relieving action, the joint function improving action, the cholesterol reducing action, the blood glucose reducing action and the diastolic blood pressure lowering action can be remarkably exerted.
The molecular weight and mass ratio of low molecular weight hyaluronic acid can be analyzed by high performance liquid chromatography using polyethylene glycol as a molecular weight marker.
分解生成物の性状は、用いる組成物の成分や組成比、プロテアーゼの種類によっても異なるが、通常は液状、さらには粘質性を帯びた液状である。分解生成物は、そのまま本発明の組成物としてもよいし、適宜精製して他の成分と組み合わせる等して本発明の組成物としてもよい。分解生成物を精製することにより、より疼痛緩和作用、関節機能改善作用、コレステロール低減作用、血糖低減作用および拡張期血圧低下作用が高い組成物とすることができる。液状の組成物は、塗布や点眼のための外用剤、飲料タイプの内服剤等として用いることができる。また、分解生成物を凍結乾燥等により乾燥した後、粉砕した場合は、粉末状の組成物を提供することが可能である。粉末状の組成物は、そのまま、もしくは他の成分を含有させて内服剤に用いてもよいし、錠剤やカプセル剤に加工してもよいし、所望の溶媒または分散媒を添加して液状とし、塗布や点眼のための外用剤や飲料タイプの内服剤等として用いてもよい。
このように、本発明の組成物は、疼痛緩和作用、関節機能改善作用、コレステロール低減作用、血糖低減作用および拡張期血圧低下作用を発揮しうる態様であれば、いかなる態様で提供されてもよい。例えば、これらの効能を明記した医薬品、医薬部外品、機能性食品（補助食品、健康食品、飴、チューインガム等も含む）、機能性飲料（ゼリー状飲料、固形分を含む流動性飲料も含む）、機能性化粧品、サプリメントとすることが可能であり、これらの使用態様は本発明の「組成物」の範囲内に含まれるものと解釈される。
The properties of the decomposition product vary depending on the components and composition ratio of the composition to be used and the type of protease, but it is usually a liquid or a viscous liquid. The decomposition product may be used as it is as the composition of the present invention, or it may be appropriately purified and combined with other components to obtain the composition of the present invention. By purifying the degradation product, it is possible to obtain a composition having a higher pain relieving action, joint function improving action, cholesterol reducing action, blood glucose reducing action and diastolic blood pressure lowering action. The liquid composition can be used as an external preparation for application and eye drops, an internal preparation of a beverage type, and the like. In addition, when the decomposition product is dried by lyophilization and the like and then pulverized, it is possible to provide a powdery composition. The powdery composition may be used as an internal preparation as it is or may be incorporated with other components, may be processed into tablets or capsules, or may be made liquid by adding a desired solvent or dispersion medium. The composition may be used as an external preparation for application or eye drops or as an internal preparation of a beverage type.
Thus, the composition of the present invention may be provided in any mode as long as it can exert pain relieving action, joint function improving action, cholesterol reducing action, blood glucose reducing action and diastolic blood pressure reducing action. . For example, it includes pharmaceuticals, quasi-drugs, functional foods (including supplements, health foods, chewing foods, chewing gum, etc.) specifying these effects, functional beverages (gelled beverages, fluid beverages including solid content). ), Functional cosmetics and supplements, and their usages are interpreted as being included within the scope of the “composition” of the present invention.
本発明の組成物には、上記分解生成物以外にも、さまざまな成分を含有させることができる。例えば、組成物に賦形剤を含有させた場合には、分解生成物と賦形剤の配合率を制御して総蛋白質量や総遊離アミノ酸量、低分子ヒアルロン酸量等の成分量を調整することができる。また、保存し易い組成物の態様として、凍結乾燥させた分解生成物を粉砕して得た粉末を賦形剤で希釈した混合粉末を挙げることができる。賦形剤としては、特に限定されないが、デキストリンが好適である。賦形剤による希釈倍率は、質量比で２〜１０倍であることが好ましく、２〜７倍であることがより好ましく、３〜５倍であることがさらに好ましい。 The composition of the present invention can contain various components in addition to the above decomposition products. For example, when an excipient is contained in the composition, the blending ratio of the decomposition product and the excipient is controlled to adjust the amount of components such as the total protein mass, the total amount of free amino acids, and the amount of low molecular weight hyaluronic acid. can do. Moreover, the mixed powder which diluted the powder obtained by grind | pulverizing the freeze-dried decomposition product with the excipient | filler can be mentioned as an aspect of the composition which is easy to store. The excipient is not particularly limited, but dextrin is suitable. The dilution ratio by the excipient is preferably 2 to 10 times by mass ratio, more preferably 2 to 7 times, and still more preferably 3 to 5 times.
本発明の組成物は、疼痛緩和作用、関節機能改善作用、コレステロール低減作用、血糖低減作用および拡張期血圧低下作用を有する。このため、本発明の組成物は、経口で摂取され、その成分が腸管から吸収された場合には、到達した関節において、その関節機能を改善し、関節における疼痛を効果的に抑制する。また、その疼痛緩和作用等により交感神経の興奮が抑えられ、拡張期血圧が適正値へ効果的に低下する。さらに、本発明の組成物の成分は脂質代謝系や糖代謝系に有益に作用して、コレステロール値および血糖値を適正値へ低下させる。これにより、加齢等による身体機能の低下を効果的に軽減することができる。ここで、本発明の組成物は、生体成分であるヒアルロン酸や蛋白質、反応が緩和な酵素を用いているため安全性が高く、経口で摂取する内服剤として使用し易いという利点がある。 The composition of the present invention has pain relieving action, joint function improving action, cholesterol reducing action, blood glucose reducing action and diastolic blood pressure reducing action. For this reason, the composition of the present invention is orally taken, and when the component is absorbed from the intestinal tract, in the reached joint, the joint function is improved and the pain in the joint is effectively suppressed. Moreover, the stimulation of the sympathetic nerve is suppressed by the pain relieving action etc., and the diastolic blood pressure is effectively lowered to the appropriate value. Furthermore, the components of the composition of the present invention beneficially act on the lipid metabolism system and sugar metabolism system to lower cholesterol and blood glucose levels to appropriate values. As a result, it is possible to effectively reduce the decrease in physical function due to aging or the like. Here, the composition of the present invention is highly safe because it uses hyaluronic acid or protein which is a biological component, and an enzyme with a mild reaction, and has the advantage of being easy to use as an oral preparation to be taken orally.
本発明の組成物の使用量は、対象とする障害によっても異なるが、例えば以下の使用量で用いることが好ましい。
例えば本発明の組成物を内服薬として経口投与する場合、その投与量は８０〜２０００ｍｇ／成人標準体重／日であることが好ましく、１日に２〜３回に分けて投与することが適当である。プロテアーゼ分解物としての投与量は、１〜１５００ｍｇ／成人標準体重／日であることが好ましい。
Although the amount of the composition of the present invention used varies depending on the target disorder, it is preferably used, for example, in the following amount.
For example, when the composition of the present invention is orally administered as an oral drug, the dosage is preferably 80 to 2000 mg / standard weight per adult for adults, and it is suitable to divide into two or three times daily . The dose as a protease degradation product is preferably 1 to 1500 mg / adult body weight / day.
［組成物の製造方法］
次に、本発明の組成物の製造方法について説明する。
本発明の組成物の製造方法は、ヒアルロン酸と蛋白質とを含有する組成物をプロテアーゼで分解する酵素処理工程を含むことを特徴とする。
本発明の組成物の製造方法は、さらに必要に応じて、この他の工程を有していてもよい。例えば、組成物が鶏冠である場合には、酵素処理工程の前に、鶏冠を小片化する小片化工程を有していてもよい。また、酵素処理工程の後に、分解生成物を濾過する濾過工程、濾過した分解生成物を乾燥した後、粉砕する製粉工程、濾過した分解生成物を精製する精製工程を有していてよい。以下において、本発明の組成物の製造方法を詳細に説明する。
[Method of producing composition]
Next, the method for producing the composition of the present invention will be described.
The method for producing the composition of the present invention is characterized in that it comprises an enzyme treatment step of degrading a composition containing hyaluronic acid and a protein with a protease.
The method of producing the composition of the present invention may further include other steps as necessary. For example, if the composition is a chicken crown, it may have a chipping step of chipping the chicken crown prior to the enzyme treatment step. In addition, after the enzyme treatment step, it may have a filtration step of filtering the decomposition product, a milling step of drying after filtering the decomposition product, and a purification step of purifying the filtration decomposition product. Hereinafter, the method for producing the composition of the present invention will be described in detail.
まず、ヒアルロン酸と蛋白質とを含有する組成物を準備する。組成物としてニワトリの鶏冠を利用する場合には、性別、年令を問わず使用し得る。ただし、採取後なるべく時間を置かずにプロテアーゼ分解に供することが好ましい。また、時間を置いてプロテアーゼ分解するときには、冷凍保存した後に解凍して使用することが好ましい。 First, a composition containing hyaluronic acid and a protein is prepared. When using the chicken crown of a chicken as a composition, it can be used regardless of gender and age. However, it is preferable to use for protease degradation without leaving time as much as possible after collection. In addition, when protease decomposition is carried out with time, it is preferable to use after thawing and then thawing.
鶏冠をプロテアーゼ分解するときには、まず鶏冠を小片化する小片化工程を行ってから、該鶏冠の小片をプロテアーゼ含有溶液に接触させることが好ましい。鶏冠は、好ましくは０．５ｃｍ角以上、より好ましくは０．７ｃｍ角以上、さらに好ましくは０．９ｃｍ角以上の小片にする。過度に細片化してしまったり、ミンチ状にしてしまうと、水分が過度に流れ出てしまったりするため好ましくない。 When the chicken crown is to be protease-degraded, it is preferable to first perform a chipping step of cutting the chicken crown into pieces, and then to contact the chicken crown pieces with a protease-containing solution. The chicken crown is preferably a piece of 0.5 cm square or more, more preferably 0.7 cm square or more, and even more preferably 0.9 cm square or more. If it is excessively fragmented or minced, it is not preferable because the water may excessively flow out.
次に、組成物をプロテアーゼで分解する酵素処理工程を行う。本発明の製造方法で用いるプロテアーゼの説明については、上記の［組成物］の欄のプロテアーゼの説明を参照することができる。酵素処理は、組成物やプロテアーゼの種類によっても異なるが、例えば組成物が鶏冠等の固形物や粉末である場合には、プロテアーゼを溶解した水溶液等の溶液（酵素液）を組成物に添加した後、一定時間放置することで行うことが好ましい。ここで、酵素液のｐＨは５．０〜１０．０であることが好ましく、処理温度は４０〜６０℃であることが好ましく、処理時間は０．５〜３．０時間であることが好ましい。また、酵素処理は、酵素液を添加した組成物を振とうしながら行うことが好ましい。 Next, the composition is subjected to an enzyme treatment step of degrading with protease. For the description of the protease used in the production method of the present invention, reference can be made to the description of the protease in the above-mentioned [Composition] column. The enzyme treatment varies depending on the composition and the type of protease, but for example, when the composition is a solid such as chicken crown or powder, a solution (enzyme solution) such as an aqueous solution in which the protease is dissolved is added to the composition It is preferable to carry out by leaving it to stand for a fixed time after that. Here, the pH of the enzyme solution is preferably 5.0 to 10.0, the treatment temperature is preferably 40 to 60 ° C., and the treatment time is preferably 0.5 to 3.0 hours . Moreover, it is preferable to perform an enzyme process, shaking the composition which added the enzyme liquid.
以上のようにして得られた分解生成物は、ろ過などの方法により鶏冠等の固形分を除去して、液状の分解生成物として用いることができる。また、凍結乾燥等により乾燥してさらに粉砕する製粉工程を行うことにより、粉末状の分解生成物として用いることもできる。これらの分解生成物は、そのまま本発明の組成物としてもよいし、適宜精製し、賦形剤等の他の成分と組み合わせる等して本発明の組成物としてもよい。 The decomposition product obtained as described above can be used as a liquid decomposition product by removing solid matter such as chicken crown by a method such as filtration. Moreover, it can also be used as a powdery decomposition product by performing a milling process of drying by lyophilization and the like and further crushing. These decomposition products may be used as they are as the composition of the present invention as they are, or may be appropriately purified and combined with other components such as an excipient to obtain the composition of the present invention.
本発明の組成物は、このように、極めて簡単な工程で製造することができる。このため、本発明の組成物の製造方法を用いることにより、有用性が高い組成物を低いコストで提供することができる。
また、濾過した分解生成物や粉末状の分解生成物を精製することにより、疼痛緩和作用、関節機能改善作用、コレステロール低減作用、血糖低減作用および拡張期血圧低下作用がより高い組成物とすることができる。分解生成物の精製方法には、分液やカラムクロマトグラフィ等の一般的な精製方法を用いることができる。
The composition of the present invention can thus be manufactured in a very simple process. Therefore, by using the method for producing the composition of the present invention, a highly useful composition can be provided at low cost.
In addition, purification of the filtered decomposition products and powdered decomposition products results in a composition having a higher pain relieving action, joint function improving action, cholesterol reducing action, blood glucose reducing action and diastolic blood pressure lowering action. Can. As a purification method of the decomposition product, general purification methods such as liquid separation and column chromatography can be used.
［組成物の用途］
上記のように、本発明の組成物は、疼痛緩和作用、関節機能改善作用、コレステロール低減作用、血糖低減作用および拡張期血圧低下作用を有する。このため、本発明の組成物は、ヒト等の動物に投与して、その疼痛を緩和する疼痛緩和剤、関節機能を改善する関節機能改善剤、血中コレステロール値を低下させるコレステロール低減剤、血糖値を低下させる血糖低減剤、または拡張期血圧を低下させる拡張期血圧低下剤として効果的に用いることができる。また、特に、疼痛緩和剤としては、膝関節痛緩和剤および腰痛緩和剤として好ましく用いることができ、関節機能改善剤としては、膝関節の可動域を開大する膝関節可動域開大剤として好ましく用いることができる。また、これらの作用の２種類以上を組み合わせた医薬品として用いてもよい。内服剤としての組成物には、必要に応じて、上記の分解生成物や賦形剤以外にも、さまざまな成分を含有させることができる。例えば、ビタミン、野菜粉末、ミネラル、酵母エキス、着色剤、増粘剤などを必要に応じて含有させることができる。これらの成分の種類は特に制限されず、含有量は目的とする機能を十分に発揮させることができる範囲内で適宜調節することができる。
[Application of composition]
As described above, the composition of the present invention has pain relieving action, joint function improving action, cholesterol reducing action, blood glucose reducing action and diastolic blood pressure reducing action. Therefore, the composition of the present invention can be administered to animals such as humans to relieve pain, joint function improving agents to improve joint function, cholesterol reduction agents to lower blood cholesterol levels, blood sugar It can be effectively used as a hypoglycemic agent that lowers the value, or as a diastolic blood pressure lowering agent that lowers the diastolic blood pressure. Moreover, in particular, as a pain relieving agent, it can be preferably used as a knee joint pain relieving agent and a back pain relieving agent, and as a joint function improving agent, as a knee joint movable range opener agent which widens the movable range of the knee joint. It can be used preferably. Moreover, you may use as a pharmaceutical which combined 2 or more types of these effect | actions. The composition as an internal preparation can contain various components in addition to the above-mentioned decomposition products and excipients, if necessary. For example, vitamins, vegetable powders, minerals, yeast extract, coloring agents, thickeners and the like can be contained as required. The kind in particular of these components is not restrict | limited, Content can be suitably adjusted in the range which can fully exhibit the target function.
以下に実施例を挙げて本発明をさらに具体的に説明する。以下の実施例に示す材料、割合、操作等は、本発明の趣旨を逸脱しない限り適宜変更することができる。したがって、本発明の範囲は以下に示す具体例により限定的に解釈されるべきものではない。 Hereinafter, the present invention will be more specifically described by way of examples. Materials, proportions, operations and the like shown in the following examples can be appropriately changed without departing from the spirit of the present invention. Therefore, the scope of the present invention should not be construed as limited by the specific examples shown below.
本実施例で製造した組成物の成分分析は下記の方法により行った。
（１）水分含有量の測定
水分含有量は、組成物の１ｇを１０５℃で３時問加熱乾燥し、精密天秤で恒量を求め定量した。
Component analysis of the composition produced in the present example was performed by the following method.
(1) Measurement of Water Content The water content was determined by heating and drying 1 g of the composition at 105 ° C. for 3 hours, determining the constant weight with a precision balance, and quantifying it.
（２）全窒素の定食
全窒素はＡＯＡＣ法に基づくセミミクロケルダール法によって定量した。
(2) Dietary Selection of Total Nitrogen Total nitrogen was quantified by the semi-micro Kjeldahl method based on the AOAC method.
（３）遊離アミノ酸の定量およびアミノ酸組成の分析
総遊離アミノ酸量はNinhydrin法によって定量した。定量には標準アミノ酸としてロイシンの検量線を作成し使用した。また、遊離アミノ酸の組成は、生体分析用カラムを装着したアミノ酸自動分析機（日立社製、L-8500型）を用いて分析した。この分析には、組成物の５０ｍｇを蒸留水に溶解し、ロータリーエバポレーダー（６０℃）で減圧乾固させた後、０．０２Ｎ塩酸５ｍＬで溶出し、ろ紙でろ過したのち、滅菌フィルターでろ過したろ液５０μＬを分析試料として使用した。
(3) Determination of free amino acids and analysis of amino acid composition The total amount of free amino acids was quantified by the Ninhydrin method. A calibration curve of leucine was prepared and used as a standard amino acid for quantification. The composition of free amino acids was analyzed using an amino acid automatic analyzer (manufactured by Hitachi, Ltd., L-8500 type) equipped with a column for biological analysis. For this analysis, 50 mg of the composition is dissolved in distilled water, dried under reduced pressure with a rotary evaporator (60 ° C.), eluted with 5 mL of 0.02 N hydrochloric acid, filtered through filter paper, and filtered through a sterile filter. 50 μL of the filtrate was used as an analysis sample.
（４）タンパク質の定量
総タンバク質量はLawry法によって決定した。標準検量線の作成には牛血清アルブミンを使用した。
(4) Protein quantification The total protein mass was determined by the Lawry method. Bovine serum albumin was used to generate a standard calibration curve.
（５）Ｎ−アセチル−Ｄ−グルコサミンの定量
Ｎ−アセチル−Ｄ−グルコサミン含有量はMorgan-Elson法で定量した。
(5) Determination of N-acetyl-D-glucosamine The N-acetyl-D-glucosamine content was quantified by the Morgan-Elson method.
（６）グルコサミノグリカンの定量
２−ニトロフェニルヒドラジンカップリング法による比色定量法で分析した。標準検量の作成には鶏冠由来ヒアルロン酸ナトリウム（和光純薬社製、ＨＡＲＣ）およびstreptococcus zooepidemicus由来のヒアルロン酸ナトリウム（和光純薬社製、ＨＡＳＺ）を用いた。
(6) Determination of glucosaminoglycan It analyzed by the colorimetric determination method by 2-nitrophenyl hydrazine coupling method. For preparation of the standard calibration, chicken crown-derived sodium hyaluronate (Hako, Wako Pure Chemical Industries, Ltd.) and sodium hyaluronate from Streptococcus zooepidemicus (Hako, Wako Pure Chemical Industries, Ltd.) were used.
（７）低分子ヒアルロン酸の分子量測定
示差屈折計（Shimazu社製、RID-10A型）を装着した高速液体クロマトグラフィー（Shimazu社製）によってヒアルロン酸の分子量を推定した。カラムとしてTSKgel G-2,500PWXL（7.8mmID×30cm）を用い、水を移動相として流速１ｍｌ／ｍｉｎで分析を行った。分子量マーカーには分子量４００、１０００、２０００、６０００の４種のポリエチレングリコール（Aldrich社製）を用いた。また、各低分子ヒアルロン酸の構成重量比は、医薬組成物とデキストリンのみのサンプルを高速液体クラマトグラフィにより分析し、組成物で現れたピークのピーク面積からデキストリンのピーク面積を差し引くことにより求めた。
(7) Measurement of Molecular Weight of Low Molecular Weight Hyaluronic Acid The molecular weight of hyaluronic acid was estimated by high performance liquid chromatography (manufactured by Shimazu) equipped with a differential refractometer (manufactured by Shimazu, RID-10A). The analysis was performed using TSKgel G-2,500 PW XL (7.8 mm ID × 30 cm) as a column and water as a mobile phase at a flow rate of 1 ml / min. As molecular weight markers, four polyethylene glycols (manufactured by Aldrich) having molecular weights of 400, 1000, 2000 and 6000 were used. In addition, the constituent weight ratio of each low molecular weight hyaluronic acid was determined by analyzing the sample consisting only of the pharmaceutical composition and dextrin by high performance liquid chromatography and subtracting the peak area of dextrin from the peak area of the peak appeared in the composition. .
［製造例］
採取したてのニワトリの鶏冠１ｋｇを約１ｃｍ角に切断して小片化し、１００℃で蒸きょうを行うことにより加熱殺菌した。この小片状の鶏冠にプロテアーゼを中心とした食物由来の酵素類を添加して４５℃で１．５時間反応させた後、攪拌して均質化した。その後、濾過して粗大な固形成分を除去し、液状の分解生成物（以下、「プロテアーゼ分解物」という）を得た。このプロテアーゼ分解物は、ｐＨ６．５、Ｂｒｉｘ値６．２０、固形分濃度５．９１質量％であった。このプロテアーゼ分解物を凍結乾燥して粉砕し、プロテアーゼ分解物の凍結乾燥粉末（組成物１）を得た。また、このプロテアーゼ分解物の凍結乾燥粉末に３倍等量（質量比）のデキストリンを添加することにより、デキストリン添加凍結乾燥粉末（組成物１’）を製造した。
[Production example]
One kg of the chicken crown of each freshly collected chicken was cut into pieces of about 1 cm square to be small pieces, and heat sterilization was carried out by steaming at 100 ° C. To this piece-like chicken crown, proteases and other food-derived enzymes were added, reacted at 45 ° C. for 1.5 hours, and stirred to homogenize. Thereafter, the resultant was filtered to remove coarse solid components to obtain a liquid decomposition product (hereinafter referred to as "protease decomposition product"). The protease degradation product had a pH of 6.5, a Brix value of 6.20, and a solid concentration of 5.91% by mass. The protease degradation product was lyophilized and pulverized to obtain a lyophilized powder (Composition 1) of the protease degradation product. Further, a dextrin-added freeze-dried powder (composition 1 ′) was produced by adding 3-fold equivalent (mass ratio) of dextrin to the freeze-dried powder of the protease degradation product.
［組成物の成分分析］
製造した組成物１’について、上記の方法により成分分析を行った。測定された一般成分の含有率を表１に示し、遊離アミノ酸の組成を表２に示し、低分子ヒアルロン酸の分子量の分析結果を表３に示す。なお、表１〜３中の「％」は「質量％」を表す。
[Component analysis of composition]
The composition analysis was performed by the method described above for the composition 1 ′ produced. The contents of the measured general components are shown in Table 1, the composition of free amino acids is shown in Table 2, and the analysis results of the molecular weight of low molecular weight hyaluronic acid are shown in Table 3. In addition, "%" in Tables 1-3 represents "mass%."
表２に示すように、組成物１’に含まれる遊離アミノ酸の中では、イソロイシン、β−アミノイソ酪酸の含有量が多く、ついで、アラニン、フェニルアラニン、アスパラギン酸、シスチン、チロシン等が多く含まれていた。
また、表３に示すように、組成物１’に含まれる低分子ヒアルロン酸は、推定分子量５０００、１５２０、１１４０、７６０および３８０の５種類からなることがわかった。また、ヒアルロン酸の繰り返し単位１つの分子量を約４００とすると、各低分子ヒアルロン酸の繰り返し単位数は、分子量の大きい順に、１３〜１４、４、３、２および１であり、質量比率は、３３％、４７％、１０％、６％および４％であった。よって、低分子ヒアルロン酸の主要成分は、分子量１５２０程度の４分子成分と分子量５０００程度の１３〜１４分子成分の２成分であることがわかった。なお、組成物１’における、分子量３８０〜５０００の低分子ヒアルロン酸の含有率は、組成物１’の全量に対して１３．４質量％であった。
As shown in Table 2, among the free amino acids contained in the composition 1 ′, the content of isoleucine and β-aminoisobutyric acid is high, and then the alanine, phenylalanine, aspartic acid, cystine, tyrosine and the like are high in content. The
In addition, as shown in Table 3, it was found that the low molecular weight hyaluronic acid contained in the composition 1 ′ consists of five types of estimated molecular weights 5000, 1520, 1140, 760 and 380. In addition, assuming that the molecular weight of one repeating unit of hyaluronic acid is about 400, the number of repeating units of each low molecular weight hyaluronic acid is 13 to 14, 4, 3, 2 and 1 in descending order of molecular weight, and the mass ratio is 33%, 47%, 10%, 6% and 4%. Therefore, it turned out that the main components of low molecular weight hyaluronic acid are two components, a four-molecular component with a molecular weight of about 1520 and a 13-14 molecular component with a molecular weight of about 5000. In addition, the content rate of the low molecular weight hyaluronic acid of the molecular weight 380-5000 in the composition 1 'was 13.4 mass% with respect to whole quantity of the composition 1'.
［組成物を含有するカプセル製剤の調製］
プロテアーゼ分解物の凍結乾燥粉末に３倍等量（質量比）のデキストリンを添加して調製したデキストリン添加凍結乾燥粉末（組成物１’）を、ゼラチンからなるカプセル内に充填してカプセル製剤（以下、「プロテアーゼ分解物含有カプセル」という）を調製した。このとき、カプセルが含むプロテアーゼ分解物の凍結乾燥粉末の量は、１カプセルあたり１５０ｍｇとした。
[Preparation of Capsule Formulation Containing Composition]
A dextrin-added freeze-dried powder (composition 1 ') prepared by adding 3-fold equivalent (mass ratio) of dextrin to a freeze-dried powder of protease degradation product is filled in a capsule consisting of gelatin to prepare a capsule preparation (described below) , “Protease degradation product-containing capsules” were prepared. At this time, the amount of lyophilized powder of the protease degradation product contained in the capsule was 150 mg per capsule.
［組成物の作用の評価］
製造例で製造したプロテアーゼ分解物の凍結乾燥粉末の作用を、日常において膝や腰の痛みに悩む健康な男女１２名（男性：６名、女性：６名）を被験者として評価した。被験者の年齢範囲は５５歳以上７７歳未満であった。具体的には、摂取開始前に、各被験者に対して所定のアンケート又は検査を行っておき、その後、プロテアーゼ分解物含有カプセルを、１日２回、４カプセルずつを水又はぬるま湯と共に摂取させ、その摂取開始から２週間後、４週間後、６週間後、８週間後に、それぞれ所定のアンケート又は検査を行った。ここで、上記のカプセル製剤の服用量は、プロテアーゼ分解物の凍結乾燥粉末の１日摂取量で１回６００ｍｇ×２回＝１２００ｍｇに相当する。
また、統計解析には、統計解析ソフト（SAS社製：SAS 9.4またはIBM社製：SPSS Statistics19）を用い、摂取開始前の評価結果と各期間経過後の評価結果を対応するデータとしてt-検定により行った。アンケート調査によって得られたスコアは、ノンパラメトリックとして取り扱い、群内での比較にはWilcoxon符号付順位和検定を行った。ここで、有意水準は両側５％とし、５％以上１０％未満を有意傾向ありと判定した。また、以下で示す図１〜８において、「*」はｐ＜０．０５を表し、「**」はｐ＜０．０１を表し、「+」はｐ＜０．１を表す。各データは、平均値±標準誤差で表すことがある。
[Evaluation of the action of the composition]
The action of the freeze-dried powder of the protease degradation product produced in the production example was evaluated as subjects using 12 healthy men and women (6 males, 6 females) who suffer from knee and lower back pain on a daily basis. The subject's age range was 55-77. Specifically, prior to the start of intake, each subject is subjected to a predetermined questionnaire or test, and then the protease degradation product-containing capsules are taken twice a day with 4 capsules each with water or lukewarm water, Predetermined questionnaires or tests were conducted two weeks, four weeks, six weeks, and eight weeks after the start of the intake. Here, the dose of the above-mentioned capsule preparation corresponds to 600 mg × twice = 1200 mg at a daily intake of the freeze-dried powder of the protease degradation product.
For statistical analysis, statistical analysis software (SAS: SAS 9.4 or IBM: SPSS Statistics 19) is used, and t-test is performed using the evaluation results before intake start and the evaluation results after each period have elapsed. Went by. The score obtained by the questionnaire survey was treated as non-parametric, and the intra-group comparison was performed by the Wilcoxon signed rank sum test. Here, the significance level was 5% on both sides, and it was determined that 5% or more and less than 10% were significant. Moreover, in FIGS. 1-8 shown below, " * " represents p <0.05, " ** " represents p <0.01, and " + " represents p <0.1. Each data may be expressed as mean ± standard error.
（膝関節痛緩和作用の評価）
（１）日本版変形性膝関節症患者機能評価尺度（JKOM）による評価
日本版変形性膝関節症患者機能評価尺度に基づき、プロテアーゼ分解物含有カプセルの摂取開始前と、摂取開始から２週間後、４週間後、６週間後および８週間後に、VAS(Visual Analogue Scale)法を用いた膝の痛みの程度のアンケートと、膝の痛みやこわばり、日常生活の状態、ふだんの生活および健康状態についてのアンケートを行った。そして、各摂取期間経過後のアンケート結果のスコアの合計と、摂取開始前のアンケート結果のスコアの合計とをWilcoxon符号付準位和検定にて比較した。摂取開始前を基準とした各摂取期間経過後のスコアの合計の変化量を図１に示す。
VAS法による痛みの程度の評価は、長さ100mmの直線の一端を「痛みなし」、もう一方の端を「これまで経験した最も激しい痛み」と設定し、被験者自身が感じる痛みの程度を直線上にマークさせ、「痛みなし」の点を起点としてマークした箇所までの長さを測定することで行った。アンケート結果のスコア化は、最も軽度の選択肢を「０」、最も重度の選択肢を「４」とし、中間の選択肢には症状の重症度に応じてそれぞれ「１」「２」「３」として行った。
アンケート結果のスコアの合計は、摂取前では２７．８±３．８、摂取２週後では２１．０±２．９、摂取４週後では１５．９±３．０、摂取６週後では１５．２±２．９、摂取８週後では１５．８±３．１であった。図１に示すように、摂取前を基準とした変化量は、摂取２週後では−６．８±１．７、摂取４週後では−１１．９±２．４、摂取６週後では−１２．７±３．１、摂取８週後では−１２．０±２．８であった。経時比較において、摂取前に比較して摂取２週後、摂取４週後、摂取６週後、摂取８週後で有意な減少が認められた。
(Evaluation of knee joint pain relieving action)
(1) Evaluation with the Japanese version of the knee osteoarthritis patient functional rating scale (JKOM) Based on the Japanese version of the knee osteoarthritic patient functional rating scale, before intake start of the protease degraded product-containing capsule and 2 weeks after intake start , 4 weeks, 6 weeks and 8 weeks later, questionnaire about the degree of knee pain using VAS (Visual Analogue Scale) method, knee pain and stiffness, condition of daily life, daily life and health condition I did a questionnaire. And the sum of the score of the questionnaire result after each intake period progress and the sum of the score of the questionnaire result before intake start were compared by the Wilcoxon signed level sum test. The total amount of change in score after each intake period has elapsed on the basis of the level before intake start is shown in FIG.
The evaluation of the degree of pain by the VAS method sets one end of a straight line 100 mm in length as “no pain” and the other end as “the most severe pain experienced so far”, and the degree of pain felt by the subject is straight This was done by marking on the top and measuring the length up to the point marked from the "no pain" point. For scoring the questionnaire results, the most mild option is “0”, the most severe option is “4”, and the middle option is “1”, “2”, “3” according to the severity of the symptoms. The
The total score of the questionnaire results is 27.8 ± 3.8 before intake, 21.0 ± 2.9 at 2 weeks after intake, 15.9 ± 3.0 at 4 weeks after intake, and 6 weeks after intake It was 15.2 ± 2.9 and 15.8 ± 3.1 after 8 weeks of intake. As shown in FIG. 1, the change based on before intake is -6.8 ± 1.7 at 2 weeks after intake, -11.9 ± 2.4 at 4 weeks after intake, and 6 weeks after intake -12.7 ± 3.1, and after 8 weeks of intake −12.0 ± 2.8. In the time-course comparison, significant reduction was observed after 2 weeks of intake, 4 weeks after intake, 6 weeks after intake and 8 weeks after intake compared with before intake.
（２）西オンタリオ・マクマスター大学変形性関節症指数（準WOMAC調査票）による評価
西オンタリオ・マクマスター大学変形性関節症指数に基づき、プロテアーゼ分解物含有カプセルの摂取開始前と、摂取開始から２週間後、４週間後、６週間後および８週間後に、下記の指標を用いて、「過去２週間を振り返っての左右の膝の痛み」についてのアンケートを行った。そして、各摂取期間経過後におけるアンケート結果のスコアの合計と、摂取開始前のアンケート結果のスコアの合計とをWilcoxon符号付準位和検定にて比較した。摂取開始前を基準とした各摂取期間経過後のスコアの合計の変化量を図２に示す。
(2) Evaluation with the Osteoarthritis Index (Square WOMAC Questionnaire), McMaster University, Western Ontario Based on the Osteoarthritis Index, McMaster University, West Ontario, before and after intake of the protease degraded product-containing capsule Two weeks later, four weeks later, six weeks later and eight weeks later, questionnaires on "pain on left and right knees in the past two weeks" were conducted using the following index. Then, the sum of the scores of the questionnaire results after each intake period and the sum of the scores of the questionnaire results before the start of intake were compared by the Wilcoxon signed level sum test. The total amount of change in score after each intake period has elapsed on the basis of the level before the start of intake is shown in FIG.
（指標とスコア）
痛みが全然ない：５点
軽い痛み：４点
中くらいの痛み：３点
強い痛み：２点
非常に激しい痛み：１点
(Indicators and scores)
No pain at all: 5 points Light pain: 4 points Medium pain: 3 points Strong pain: 2 points Extremely severe pain: 1 point
アンケート結果のスコアの合計は、摂取前では３７．３±１．９、摂取２週後では４２．１±１．８、摂取４週後では４３．３±１．６、摂取６週後では４５．１±１．５、摂取８週後では４４．６±１．５であった。図２に示すように、摂取前を基準とした変化量は、摂取２週後では４．８±１．１、摂取４週後では６．０±１．６、摂取６週後では７．８±１．９、摂取８週後では７．３±２．０であった。経時比較において、摂取前に比較して摂取２週後、摂取４週後、摂取６週後、摂取８週後で有意な増加が認められた。 The total score of the questionnaire results is 37.3 ± 1.9 before intake, 42.1 ± 1.8 at 2 weeks after intake, 43.3 ± 1.6 at 4 weeks after intake, and 6 weeks after intake It was 45.1 ± 1.5 and 44.6 ± 1.5 after 8 weeks of intake. As shown in FIG. 2, the change based on the intake before intake is 4.8 ± 1.1 at 2 weeks after intake, 6.0 ± 1.6 at 4 weeks after intake, and 7 at 6 weeks after intake. It was 8 ± 1.9 and 7.3 ± 2.0 after 8 weeks of intake. In the time-course comparison, significant increases were observed two weeks after intake, four weeks after intake, six weeks after intake, and eight weeks after intake compared with before intake.
また、西オンタリオ・マクマスター大学変形性関節症指数に基づき、プロテアーゼ分解物含有カプセルの摂取開始前と、摂取開始から２週間後、４週間後、６週間後および８週間後に、下記の指標を用いて、「過去２週間を振り返っての膝の症状の為の、日常的な活動への影響」についてのアンケート（身体機能についてのアンケート）を行った。そして、各摂取期間経過後のアンケート結果のスコアの合計と、摂取開始前のアンケート結果のスコアの合計とをWilcoxon符号付準位和検定にて比較した。摂取開始前を基準とした各摂取期間経過後のスコアの合計の変化量を図３に示す。 In addition, based on the Osteoarthritis Index at McMaster University in Western Ontario, the following indicators are given before the start of intake of the protease degradation product-containing capsule, and two weeks, four weeks, six weeks, and eight weeks after the start of intake: Using the survey, we conducted a questionnaire on "impact on daily activities for knee symptoms for the past two weeks" (a questionnaire on physical function). And the sum of the score of the questionnaire result after each intake period progress and the sum of the score of the questionnaire result before intake start were compared by the Wilcoxon signed level sum test. The amount of change in the total score after each intake period has elapsed on the basis of that before intake start is shown in FIG.
（指標とスコア）
日常的な活動が全然難しくない：５点
日常的な活動が少し難しい：４点
日常的な活動がある程度難しい：３点
日常的な活動が難しい：２点
日常的な活動がかなり難しい：１点
(Indicators and scores)
Daily activities are not difficult at all: 5 points Daily activities are slightly difficult: 4 points Daily activities are difficult to some extent: 3 points Daily activities are difficult: 2 points Daily activities are quite difficult: 1 point
アンケート結果のスコアの合計は、摂取前では６６．２±３．６、摂取２週後では７３．０±２．５、摂取４週後では７４．３±２．７、摂取６週後では７５．３±２．５、摂取８週後では７４．９±２．３であった。図３に示すように、摂取前を基準とした変化量は、摂取２週後では６．８±１．８、摂取４週後では８．２±２．３、摂取６週後では９．２±２．９、摂取８週後では８．８±２．９であった。経時比較において、摂取前に比較して摂取２週後、摂取４週後、摂取６週後、摂取８週後で有意な増加が認められた。 The total score of the questionnaire results is 66.2 ± 3.6 before intake, 73.0 ± 2.5 at 2 weeks after intake, 74.3 ± 2.7 at 4 weeks after intake, and 6 weeks after intake It was 75.3 ± 2.5 and 74.9 ± 2.3 after 8 weeks of intake. As shown in FIG. 3, the amount of change based on preintake is 6.8 ± 1.8 two weeks after intake, 8.2 ± 2.3 four weeks after intake, and 9. weeks after intake. It was 2 ± 2.9 and 8.8 ± 2.9 after 8 weeks of intake. In the time-course comparison, significant increases were observed two weeks after intake, four weeks after intake, six weeks after intake, and eight weeks after intake compared with before intake.
（腰痛緩和作用の評価）
腰痛症患者機能評価質問表（JLEQ）に基づき、プロテアーゼ分解物含有カプセルの摂取開始前と、摂取開始から２週間後、４週間後、６週間後および８週間後に、それぞれ、VAS法を用いた腰の痛みの程度のアンケートと、数日間の腰の痛み、数日間の腰痛による生活上の問題およびこの１か月の状態についてのアンケートを行った。そして、各摂取期間経過のアンケート結果のスコアの合計と、摂取開始前のアンケート結果のスコアの合計とをWilcoxon符号付準位和検定にて比較した。摂取開始前を基準とした各摂取期間経過後のスコアの合計の変化量を図４に示す。
VAS法による痛みの程度の評価は、長さ100mmの直線の一端を「痛みなし」、もう一方の端を「これまで経験した最も激しい痛み」と設定し、被験者自身が感じる痛みの程度を直線上にマークさせ、「痛みなし」の点を起点としてマークした箇所までの長さを測定することで行った。アンケート結果のスコア化は、最も軽度の選択肢を「０」、最も重度の選択肢を「４」とし、中間の選択肢には症状の重症度に応じてそれぞれ「１」「２」「３」として行った。
アンケート結果のスコアの合計は、摂取前では３８．３±７．３、摂取２週後では２８．３±６．５、摂取４週後では２１．３±５．５、摂取６週後では２０．１±４．３、摂取８週後では１７．８±４．１であった。図４に示すように、摂取前を基準とした変化量は、摂取２週後では−１０．０±４．０、摂取４週後では−１６．９±４．１、摂取６週後では−１８．２±４．４、摂取８週後では−２０．５±４．９であった。経時比較において、摂取前に比較して摂取２週後、摂取４週後、摂取６週後、摂取８週後で有意な減少が認められた。
(Evaluation of back pain alleviation effect)
Based on the Low Back Pain Patient Function Evaluation Questionnaire (JLEQ), the VAS method was used before intake initiation of the protease degradation product-containing capsule, and two weeks, four weeks, four weeks, six weeks and eight weeks after intake start, respectively. A questionnaire on the degree of lower back pain, and on the problems of lower back pain for several days, back pain for several days, and the condition of this month were conducted. And the total of the score of the questionnaire result of each intake period progress and the sum of the score of the questionnaire result before intake start were compared by the Wilcoxon signed level sum test. The total amount of change in score after each intake period has elapsed on the basis of that before intake start is shown in FIG.
The evaluation of the degree of pain by the VAS method sets one end of a straight line 100 mm in length as “no pain” and the other end as “the most severe pain experienced so far”, and the degree of pain felt by the subject is straight This was done by marking on the top and measuring the length up to the point marked from the "no pain" point. For scoring the questionnaire results, the most mild option is “0”, the most severe option is “4”, and the middle option is “1”, “2”, “3” according to the severity of the symptoms. The
The total score of the questionnaire results is 38.3 ± 7.3 before intake, 28.3 ± 6.5 after 2 weeks intake, 21.3 ± 5.5 after 4 weeks intake, and 6 weeks after intake It was 20.1 ± 4.3 and 17.8 ± 4.1 after 8 weeks of intake. As shown in FIG. 4, the amount of change based on the intake before intake is −10.0 ± 4.0 at 2 weeks after intake, −16.9 ± 4.1 at 4 weeks after intake, and at 6 weeks after intake -18.2 ± 4.4, 8 weeks after intake was -20.5 ± 4.9. In the time-course comparison, significant reduction was observed after 2 weeks of intake, 4 weeks after intake, 6 weeks after intake and 8 weeks after intake compared with before intake.
［膝関節可動域開大作用の評価］
プロテアーゼ分解物含有カプセルの摂取開始前と、摂取開始から２週間後、４週間後、６週間後および８週間後に、東大式角度計30cm（Z813-153A））を用いて、整形外科専門医による膝関節自動可動域の測定を実施した。各摂取期間経過後の膝関節自動可動域の左右の平均値と、摂取開始前の膝関節自動可動域の左右の平均値とをt-検定により比較した。摂取開始前を基準とした、各摂取期間経過後の膝関節自動可動域の左右の平均値の変化量を図５に示す。
膝関節自動可動域は、摂取前では１３７．３８±１．８１度、摂取２週後では１３８．５０±１．７１度、摂取４週後では１３８．１３±２．４２度、摂取６週後では１４０．７９±１．６２度、摂取８週後では１４１．３８±１．７７度であった。図５に示すように、摂取前を基準とした変化量は、摂取２週後では１．１３±０．５６度、摂取４週後では０．７５±０．９３度、摂取６週後では３．４２±１．４８度、摂取８週後では４．００±１．７６度であった。経時比較において、摂取前に比較して摂取２週後で増加の傾向、摂取６週後、摂取８週後で有意な増加が認められた。
[Evaluation of knee joint movement range widening action]
Knees by an orthopedic specialist using the University of Tokyo-style angle meter 30 cm (Z813-153A) before start of intake of the protease degradation product-containing capsule and after 2, 4 weeks, 6 weeks and 8 weeks after start of intake Measurement of joint automatic movement range was performed. The average value of the right and left of the knee joint automatic movement range after each intake period was compared with the average value of the right and left of the knee joint automatic movement range before the start of intake by t-test. The amount of change of the average value of the right and left of the knee joint automatic movement range after each intake period on the basis of before intake start is shown in FIG.
Knee joint automatic movement range is 137.38 ± 1.81 degrees before intake, 138.50 ± 1.71 degrees after intake two weeks, 138.13 ± 2.42 degrees after intake four weeks, intake 6 weeks It was 140.79 ± 1.62 degrees later and 141.38 ± 1.77 degrees eight weeks after intake. As shown in FIG. 5, the change based on before intake is 1.13 ± 0.56 degrees two weeks after intake, 0.75 ± 0.93 degrees four weeks after intake, and six weeks after intake It was 3.42 ± 1.48 degrees and 4.00 ± 1.76 degrees at 8 weeks after intake. In the time-course comparison, there was a tendency for an increase after 2 weeks of intake compared with before intake, and a significant increase after 6 weeks of intake and 8 weeks after intake.
［コレステロール低減作用および血糖低減作用の評価］
プロテアーゼ分解物含有カプセルの摂取開始前と摂取開始から８週間後に、採血を行って血中総コレステロール（T-cho）値と血中グリコヘモグロビン（HbA1c）値を測定し、それらの測定値を摂取開始前と摂取開始８週間後でt-検定により比較した。ここで、グリコヘモグロビン（HbA1c）はヘモグロビンに血中のブドウ糖が結合したもので、血糖値が高いもの程、血中グリコヘモグロビン（HbA1c）値も高い値になる。
摂取開始前を基準とした８週間経過後の血中総コレステロール値の変化量を図６に示す。
血中総コレステロール値は、摂取前では２２６．６±９．８ｍｇ／ｄＬ、摂取８週間後では２１４．３±７．９ｍｇ／ｄＬであった。図６に示すように、摂取前を基準とした変化量は、摂取８週間後では−１２．３±４．２ｍｇ／ｄＬであった。経時比較において、摂取前に比較して摂取８週後で有意な減少が認められた。
また、摂取開始前を基準とした８週間経過後の血中グリコヘモグロビン値の変化量を図７に示す。
血中グリコヘモグロビン値は、摂取前では５．４７±０．０８％、摂取８週後では５．２９±０．０７％であった。図７に示すように、摂取前を基準とした変化量は、摂取８週後では−０．１８±０．０３％であった。経時比較において、摂取前に比較して摂取８週後で有意な減少が認められた。
[Evaluation of cholesterol reduction action and blood sugar reduction action]
Blood is collected before and 8 weeks after the start of intake of the protease degraded product-containing capsule, and blood total cholesterol (T-cho) and blood glycohemoglobin (HbA1c) levels are measured, and those measured values are taken. Comparison was made by t-test before start and 8 weeks after start of intake. Here, glycohemoglobin (HbA1c) is a combination of hemoglobin and glucose in blood, and the higher the blood glucose level, the higher the blood glycohemoglobin (HbA1c) value.
The amount of change in total blood cholesterol level after 8 weeks based on the level before the start of intake is shown in FIG.
The total blood cholesterol level was 226.6 ± 9.8 mg / dL before intake and 214.3 ± 7.9 mg / dL eight weeks after intake. As shown in FIG. 6, the amount of change based on before intake was −12.3 ± 4.2 mg / dL after 8 weeks of intake. In comparison over time, a significant decrease was observed 8 weeks after intake compared to before intake.
Further, the amount of change in blood glycohemoglobin level after 8 weeks based on the level before the start of intake is shown in FIG.
Blood glycohemoglobin levels were 5.47 ± 0.08% before intake and 5.29 ± 0.07% after 8 weeks of intake. As shown in FIG. 7, the amount of change based on before intake was −0.18 ± 0.03% after 8 weeks of intake. In comparison over time, a significant decrease was observed 8 weeks after intake compared to before intake.
［拡張期血圧低下作用の評価］
プロテアーゼ分解物含有カプセルの摂取開始前と、摂取開始から２週間後、４週間後、６週間後および８週間後に、電子血圧計（テルモ株式会社製、H55 エレマーノ血圧計）を用いて血圧を測定し、各摂取期間経過後の拡張期血圧と、摂取前の拡張期血圧とをt-検定により比較した。摂取開始前を基準とした各摂取期間経過後の拡張期血圧の変化量を図８に示す。
拡張期血圧は、摂取前では７５．７±３．２ｍｍＨｇ、摂取２週後では７４．５±３．７ｍｍＨｇ、摂取４週後では７５．１±３．６ｍｍＨｇ、摂取６週後では７３．０±３．２ｍｍＨｇ、摂取８週後では６９．５±３．３ｍｍＨｇであった。図８に示すように、摂取前を基準とした変化量は、摂取２週後では−１．２±２．６ｍｍＨｇ、摂取４週後では−０．６±２．３ｍｍＨｇ、摂取６週後では−２．７±２．２ｍｍＨｇ、摂取８週後では−６．２±２．１ｍｍＨｇであった。経時比較において、摂取前に比較して摂取８週後で有意な減少が認められた。
[Evaluation of diastolic blood pressure lowering action]
Blood pressure was measured using an electronic sphygmomanometer (H55 Elemano sphygmomanometer manufactured by Terumo Co., Ltd.) before, and after 2, 4, 6, 6, and 8 weeks after intake of the protease degraded product-containing capsule. The diastolic blood pressure after each intake period was compared with the diastolic blood pressure before intake by t-test. The amount of change in diastolic blood pressure after each intake period is shown in FIG.
The diastolic blood pressure is 75.7 ± 3.2 mmHg before intake, 74.5 ± 3.7 mmHg after 2 weeks intake, 75.1 ± 3.6 mmHg after 4 weeks intake, 73.0 after 6 weeks intake It was ± 3.2 mmHg, and 89.5 weeks after ingestion it was 69.5 ± 3.3 mmHg. As shown in FIG. 8, the amount of change based on before intake is −1.2 ± 2.6 mmHg at 2 weeks after intake, −0.6 ± 2.3 mmHg at 4 weeks after intake, and 6 weeks after intake It was −2.7 ± 2.2 mmHg, and after 8 weeks of intake was −6.2 ± 2.1 mmHg. In comparison over time, a significant decrease was observed 8 weeks after intake compared to before intake.
以上の結果から、本発明の組成物が含むプロテアーゼ分解物が、膝関節痛緩和作用、腰痛緩和作用、膝関節可動域開大作用、コレステロール低減作用、血糖低減作用および拡張期血圧低下作用を顕著に示すことを確認することができた。
プロテアーゼ分解物の凍結乾燥粉末がこれらの作用を示すメカニズムは明らかではないが、以下のように推測される。
まず、疼痛緩和作用と関節機能改善作用については、プロテアーゼ分解物が含む低分子ヒアルロン酸が関節の潤滑性を改善するとともに、関節軟骨の保護や破壊抑制、軟骨分化促進、滑膜細胞の保護に効果的に寄与し、さらに炎症を抑えるように機能したことが、これらの作用を生じさせたものと推測される。
拡張期血圧低下作用については、主としてプロテアーゼ分解物の疼痛緩和作用の影響によると考えられる。すなわち、関節痛や腰痛などにより優位になっていた交感神経の興奮が、プロテアーゼ分解物の疼痛緩和作用によって抑制され、拡張期血圧の低下につながったと推測される。
総コレステロール値および血糖値の低下については、プロテアーゼ分解物が含む成分が腸内細菌フローラおよび血清コレステロール代謝に有益な影響を与えたことによるものと推測される。
From the above results, the protease degradation product contained in the composition of the present invention has remarkable knee joint pain relieving action, low back pain relieving action, knee joint movable area widening action, cholesterol reducing action, blood glucose reducing action and diastolic blood pressure lowering action. I was able to confirm that
Although the mechanism by which the freeze-dried powder of the protease degradation product exhibits these effects is not clear, it is presumed as follows.
First, for pain relieving action and joint function improving action, low molecular weight hyaluronic acid contained in the protease degradation product improves the lubricity of the joint, and also protects and suppresses destruction of articular cartilage, promotes cartilage differentiation, and protects synovial cells. It is inferred that the function to effectively contribute and further to suppress inflammation is the cause of these effects.
The diastolic blood pressure lowering action is considered to be mainly due to the effect of the pain relieving action of the protease degradation product. That is, it is inferred that sympathetic nerve excitation, which has become dominant due to arthralgia, back pain, etc., is suppressed by the pain relieving action of the protease degradation product, leading to a decrease in diastolic blood pressure.
It is presumed that the components contained in the protease degradation product have a beneficial effect on intestinal bacterial flora and serum cholesterol metabolism with respect to the reduction of total cholesterol level and blood glucose level.
本発明によれば、疼痛緩和作用、関節機能改善作用、コレステロール低減作用、血糖低減作用および拡張期血圧低下作用を有する組成物を低コストで提供することができる。このため、本発明の組成物を用いれば、加齢等による身体機能の低下を軽減しうる、安価な内服剤を提供することができる。このため、本発明は産業上の利用可能性が高い。 According to the present invention, it is possible to provide at low cost a composition having a pain relieving action, joint function improving action, cholesterol reducing action, blood glucose reducing action and diastolic blood pressure reducing action. For this reason, if the composition of the present invention is used, it is possible to provide an inexpensive oral preparation which can reduce the decrease in physical function due to aging and the like. For this reason, the present invention has high industrial applicability.
Claims (16)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017247605A JP6303063B1 (en) | 2017-12-25 | 2017-12-25 | Cholesterol reducing agent and method for producing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017247605A JP6303063B1 (en) | 2017-12-25 | 2017-12-25 | Cholesterol reducing agent and method for producing the same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017221967A Division JP6307201B1 (en) | 2017-11-17 | 2017-11-17 | Knee joint range of motion expander and method for producing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP6303063B1 JP6303063B1 (en) | 2018-03-28 |
| JP2019055934A true JP2019055934A (en) | 2019-04-11 |
Family
ID=61756686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017247605A Active JP6303063B1 (en) | 2017-12-25 | 2017-12-25 | Cholesterol reducing agent and method for producing the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6303063B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6279801B1 (en) | 2017-09-19 | 2018-02-14 | 株式会社らいむ | Composition and method for producing the same |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6622613B2 (en) * | 2016-02-12 | 2019-12-18 | 株式会社らいむ | Antioxidant |
-
2017
- 2017-12-25 JP JP2017247605A patent/JP6303063B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6303063B1 (en) | 2018-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sierra et al. | Effects of ispaghula husk and guar gum on postprandial glucose and insulin concentrations in healthy subjects | |
| CN103083642B (en) | For the aloe preparation that skin strengthens | |
| JP3020387B2 (en) | Antiviral substance | |
| JP5639604B2 (en) | Pharmaceutical composition for inhibiting inflammation | |
| KR20010029674A (en) | Skin care agent, and health and beauty care food | |
| WO2019058665A1 (en) | Composition, and method for producing same | |
| CN108323764B (en) | Method for extracting eggshell membrane polypeptide and preparing bone joint health product | |
| JP6622613B2 (en) | Antioxidant | |
| JP2020189870A (en) | Composition and kit for treating joints | |
| JP2009051877A (en) | New hyaluronic acid and/or salt thereof, food composition and oral medicinal composition using the same, and oral skin ameliorating agent or oral skin water content-increasing agent comprising the hyaluronic acid and/or the salt thereof as active ingredient | |
| US20150147407A1 (en) | Composition for preventing or treating osteoarthritis | |
| JP6303065B1 (en) | Diastolic blood pressure lowering agent and method for producing the same | |
| JP6303064B1 (en) | Blood sugar reducing agent and method for producing the same | |
| JP6303063B1 (en) | Cholesterol reducing agent and method for producing the same | |
| JP6307201B1 (en) | Knee joint range of motion expander and method for producing the same | |
| CN109589400B (en) | Composition with neuroprotective effect | |
| JP6435072B1 (en) | Method for producing protease-decomposing composition, method for producing fibroblast growth promoter, and method for producing collagen production promoter | |
| CN105982911A (en) | Preparation method of high-viscoelasticity injection composed of glucosamine and sodium hyaluronate | |
| KR20080087941A (en) | A composition containing the low molecular weight hyaluronic acid for improving skin wrinkles and skin peeling | |
| JP7140436B1 (en) | Eye condition improving agent and method for producing the same | |
| JP6457281B2 (en) | Modified hyaluronic acid and / or salt thereof, and method for producing the same | |
| JP5723919B2 (en) | Method for producing novel hyaluronic acid and / or salt thereof, and food composition, oral skin improving agent or oral skin water content increasing agent containing hyaluronic acid and / or salt thereof | |
| JP6198867B2 (en) | Wound treatment | |
| JP2017088545A (en) | Ultraviolet hazard alleviating composition, method for producing ultraviolet hazard alleviating composition, additive for culture medium, additive for microorganism diluent, culture medium, microorganism diluent, external preparation and cosmetics | |
| Suekawa et al. | Development of hyaluronic acid-collagen-proteoglycan complex (Hyaluco PG) by hot water extraction from salmon nasal cartilage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171226 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171226 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20171226 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20180112 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180130 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180227 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180305 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6303063 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |